Establishing a UK Medicines Manufacturing Innovation Centre

建立英国药品制造创新中心

• 批准号: 104208
• 金额: $ 2803.24万
• 依托单位: CENTRE FOR PROCESS INNOVATION LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104208
• 关键词: Establishing; UK; Medicines; Manufacturing; Innovation

The UK’s pharmaceutical sector is the sixth largest contributor to UK’s net export, contributing approximately £32.4 p.a. [3]. However, the sector's output dropped by an average of approximately 3.2% per year between 2008 and 2013 [4]. This decline has been partly attributed to reduced R&D investment and the lack of government investment in radical and disruptive manufacturing innovations. Despite the UK’s strong global position (3rd) in pharma R&D [11], it currently ranks 8th in pharma manufacturing, trailing the US, Japan, China, Germany, France, Brazil, and Italy [12]. The UK’s weakness in manufacturing innovation has led to it losing out to competing countries on the final manufacture of high value innovative pharma/fine chemical products, leading to increased UK imports of materials and finished products, reduced self-sufficiency, increased vulnerability to supply shortages, loss of high value jobs, and loss of manufacturing knowhow and skills [8]. As a measure to avert the above decline and to boost the competitiveness of the UK’s pharmaceutical sector, the Centre for Process Innovation (CPI) and University of Strathclyde are partnering with UK industry stakeholders and UK Government to create a state-of-the-art Medicines Manufacturing Innovation Centre (MMIC), dedicated to accelerating the development and industrial adoption of transformative manufacturing innovations in small molecule pharmaceuticals (which make up the majority of medicines) and fine chemicals (of which >70% are consumed by the pharmaceutical industry).

英国制药行业是英国净出口的第六大贡献者，每年贡献约32.4英镑。然而，在2008年至2013年期间，该行业的产量平均每年下降约3.2%。这种下降的部分原因是研发投资减少，以及政府缺乏对激进和颠覆性制造业创新的投资。尽管英国在制药研发领域的全球排名第三，但目前在制药制造领域排名第八，落后于美国、日本、中国、德国、法国、巴西和意大利。英国在制造业创新方面的弱点导致其在高价值创新制药/精细化工产品的最终制造方面输给了竞争国家，导致英国材料和成品的进口增加，自给自足程度降低，供应短缺的脆弱性增加，高价值工作岗位的流失，以及制造业知识和技能的丧失。为了避免上述衰退并提高英国制药行业的竞争力，过程创新中心（CPI）和斯特拉斯克莱德大学正在与英国行业利益相关者和英国政府合作，创建一个最先进的药品制造创新中心（MMIC）。致力于加速小分子药物（占药物的大部分）和精细化学品（制药行业消耗了其中的70%）的变革性制造创新的发展和工业采用。